E&S Healthcare promises a healthier life for mankind.

DxMe® BC

DxMe® BC


Blood-based breast cancer in vitro diagnostic kit using ELISA

The current gold standard of early detection of breast cancer is mammography that has inevitable weak points such as cost, discomfort, and radiation exposure. Besides, an additional examination might be necessary for better diagnosis of dense breasts.
Our breast cancer diagnostic kit, DxMe® BC, measures a specific protein biomarker from the blood by ELISA regardless of breast conditions. It can help detect breast cancer exactly. The accuracy can be maximally enhanced when it is accompanied with mammography.

Item Particular
Test Format Sandwich ELISA
Brand Name DxMe® BC Kit
Specificity 96.43%1
Sensitivity 97.32%1
Cut-off 11.4 ng/ml1
99% Reference range 3.4 ~ 18.8ng/ml
Detection Range 3.4 ~ 44.4ng/ml
Tests per kit 88 Tests
QMS Certificates ISO 13485
Product registration European union
New Zealand
Stability ≤ 12 months (at 4℃)
  • Specificity : Ability to distinguish normal group from the tester group
  • Sensitivity : Ability to distinguish abnormal group (patient group) from tester group
  • Cut-off-Value : Reference value for distinguishing between normal and abnormal groups
  • 1 The blood Trx1 level could correct mis- or incompletely judged mammography with 93% efficency1.
  • 2 When mammography and Trx1 level were analyzed together, the accuracy was near 100% 1.
  • 1 The levels of blood Trx` were measured from 308 biopsy-confirmed BC patients, 82 breast benign tumor bearers, and 254 woman without any disease (total of 336 women as a control group)1.
  • 2 The clinical sensitivity and specificity were 96.43% and 97.32%, respectively.
  • 3 The AUC was 0.985 (95% CI: 0.972 to 0.993)1.
  • 4 The level of blood Trx1 could differentiate BC regardless of characteristics of BC including stage 1, 2.
  • 1 The blood Trx1 level was decreased dramatically after surgery, and it was likely to depend on the presence or absence of a tumor mass3.
  • 2 The blood Trx1 level has potential as a monitoring biomaker to assist the management of BC patients after treatment 3.
Clinical evidence
Scientific Articles
  • 1 Kim, Y. (2022, July). Clinical Evaluation of Thioredoxin 1 in the Blood as a Novel Biomarker to Detect Breast Cancer. Poster presented at American Association for Clinical Chemistry annual scientific meeting & Clinical Lab Expo, Chicago, IL, U.S., Abstract retrieved from
  • 2 Lee, Y.J., Kim, Y., Choi, B.B., Kim, J.R., Ko, H.M. Suh, K.H. & Lee, J.S. (2022). The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer. BMC Cancer, 22:12
  • 3 Ko. H.M. (2022, April). The Blood Level of Thioredoxin 1 as a Biomarker for the Monitoring of Breast Cancer Patients Underwent Surgery. Poster presented at Global Breast Cancer Conference, Seoul, KR, Abstract retrieved from

Breast Cancer

  • No. 1

    Gynecologic cancer in 1 out of 5 women

  • 70%

    Incidence of women
    in their 40s/50s

  • X4

    Sharp increase over 15 years

    (As of 2017)

  • Over

    Early detection survival rate

  • 51.9

    median age of patient

(KBCS 2020)

The Statistics
The Statistics
Incidence & Mortality
Incidence & Mortality
Golden Standard(Mammography)
Golden Standard(Mammography)
Current Diagnostics
Current Diagnostics